Market revenue in 2023 | USD 700.5 million |
Market revenue in 2030 | USD 1,148.8 million |
Growth rate | 7.3% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | BD, Danaher Corp, Koninklijke Philips NV, Qiagen NV, Thermo Fisher Scientific Inc, Myriad Genetics Inc, Argon Medical Devices, Roche Holding AG ADR, Hologic Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.27% in 2023. Horizon Databook has segmented the France breast cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
This major factors driving the growth of the France market are, increase in prevalence of target diseases, technological advancements, and consumer awareness. In addition, France has one of the highest breast cancer incidences globally. According to data published by the WHO in 2018, approximately 56,162 new breast cancer cases were observed in France.
In addition, presence of key manufacturers and growth in strategic initiatives undertaken by these key players can make a positive impact on the market in France. As per Institut-Curie in 2017, screening program is offered for women aged between 50 to 74, which is conducted via public insurance.
In May 2018, Uni cancer group selected Blue Print Molecular Subtyping test and Mamma Print Breast Cancer Risk of Recurrence test for use in its 18 cancer facilities. This displays the interest of the country’s hospitals in genetic diagnosis to mitigate the risks and treat patients better.
Horizon Databook provides a detailed overview of country-level data and insights on the France breast cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into France breast cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account